| Literature DB >> 30840707 |
Márcia Aires Rodrigues de Freitas1,2, Alice Vieira da Costa2, Luciana Alves Medeiros2, Lucas Moreira Cunha2, Ubirajara Coutinho Filho3, Mario da Silva Garrote Filho2, Angélica Lemos Debs Diniz1, Nilson Penha-Silva2.
Abstract
The objective of this study was to analyze the relationships of osmotic and mechanical stability of erythrocytes with anthropometric, biochemical, hematologic and hemodynamic variables in pregnant women with preeclampsia (PE). The studied population consisted of 20 normotensive patients and 16 patients with PE. Patients with PE presented worse gestational outcome, greater hematologic impairment, erythrocytes osmotically more stable in vitro, but in conditions of isotonicity with the in vivo medium, in addition to hyperflow in orbital territory, when compared to normotensive patients. The correlation analysis between anthropometric, hematologic and hemodynamic variables in patients with PE indicated that erythrocytes with lower volumes and lower levels of hemoglobin favor the occurrence of a better gestational outcome, because they are more stable and because they are associated with a decrease in the hemodynamic changes present in the disease. This should mean that the tendency to microcytosis, probably due to a mechanism of compensatory mechanical selection, is a desirable characteristic in the disease.Entities:
Mesh:
Year: 2019 PMID: 30840707 PMCID: PMC6402648 DOI: 10.1371/journal.pone.0212763
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of the study population.
| Parameters | Normotensive | Preeclampsia | p | |
|---|---|---|---|---|
| Maternal Age (years) | 25.60 ± 6.36 (20) | 26.19 ± 7.92 (16) | 0.811 | |
| Ethnic Group Distribution | 0.648 | |||
| White | 65% (13) | 50.0% (8) | ||
| Mixed | 20% (4) | 31.3% (5) | ||
| Black | 15% (3) | 18.8% (3) | ||
| Weight Gain (kg) | 10 (10–11) (17) | 15.5 (14.38–20) (8) | 0.002 | |
| Parity | 0.119 | |||
| Nulliparous | 21.05% (4) | 50% (8) | ||
| Multiparous | 78.95% (15) | 50% (8) | ||
| Body Mass Index (kg/m2) | ||||
| Before Pregnancy | 24.70 ± 4.80 (19) | 26.63 ± 4.72 (7) | 0.367 | |
| At the end of pregnancy | 29.7 (27.9–31.5) (18) | 33.8 (30.6–39.0) (13) | 0.042 | |
| Gestacional Age (weeks) | 40 (39.5–40.5) (20) | 37.5 (35–39) (15) | 0.001 | |
| Birth Weight (kg) | 3.6 ± 0.4 (19) | 2.7 ± 0.9 (15) | <0.001 | |
| Placenta Weight (g) | 590 (555–685) (19) | 490 (417–597.5) (16) | 0.010 | |
| Delivery Type | 0.504 | |||
| Cesarean | 78.9% (15) | 87.5% (14) | ||
| Vaginal Birth | 21.1% (4) | 12.5% (2) | ||
| Apgar Score at 1 minute | 0.428 | |||
| 1 | 7.7% (1) | |||
| 4 | ||||
| 5 | ||||
| 6 | ||||
| 7 | 7.7% (1) | |||
| 8 | 66.7% (12) | 53.8% (7) | ||
| 9 | 33.3% (6) | 23.1% (3) | ||
| 10 | 7.7% (1) | |||
| Apgar Score at 5 minute | 0.940 | |||
| 8 | 11.1% (2) | 14.3% (2) | ||
| 9 | 72.2% (13) | 64.3% (9) | ||
| 10 | 16.7% (3) | 21.4% (3) | ||
| Sex of the Newborn | 0.179 | |||
| Male | 65% (13) | 40% (6) | ||
| Female | 35% (7) | 60% (9) | ||
| Blood Group | 0.475 | |||
| A (–) | 5.0% (1) | 6.3% (1) | ||
| A (+) | 20% (4) | 43.8% (7) | ||
| B (–) | - | |||
| B (+) | 10% (2) | 18.8% (3) | ||
| O (–) | 10% (2) | 6.3% (1) | ||
| O (+) | 50% (10) | 25% (4) | ||
| AB (–) | - | |||
| AB (+) | 5% (1) | |||
| Systolic Blood Pressure (mmHg) | 120 (110–120) (19) | 155 (140–165) (16) | 0.001 | |
| Diastolic Blood Pressure (mmHg) | 75 (70–80) (19) | 100 (90–110) (16) | 0.001 | |
| Red Blood Cell Count (106 cells/mm3) | 4.08 ± 0.38 (20) | 4.11 ± 0.40 (15) | 0.991 | |
| Hematocrit (%) | 34.99 ± 2.84 (20) | 34.37 ± 3.71 (15) | 0.596 | |
| Hemoglobin (g/dL) | 12.03 ± 1.07 (20) | 11.73 ± 1.51 (15) | 0.521 | |
| MCV (fL) | 86.01 ± 4.85 (20) | 83.61 ± 6.32 (15) | 0.232 | |
| MCH (pg) | 29.55 ± 2.30 (20) | 27.30 ± 4.40 (15) | 0.202 | |
| MCHC (g/dL) | 34.17 ± 1.12 (20) | 33.57 ± 1.32 (15) | 0.168 | |
| RDW (%) | 13.67 ±1.48 (20) | 13.80 ± 2.10 (15) | 0.603 | |
| Reticulocytes Index (%) | 0.95 (0.4–1.7) (18) | 1.4 (0.8–3.1) (15) | 0.036 | |
| Platelet Count (103 cel/mm3) | 215.0 ± 48.8 (20) | 215.7 ± 61.61 (15) | 0.968 | |
| MPV (fL) | 11.16 (10.5–12.2) (20) | 10.40 (10–12) (15) | 0.254 | |
| Total Cholesterol (mg/dL) | 215.9 (184–249) (19) | 208.02 (184–232) (14) | 0.706 | |
| HDL-Cholesterol (mg/dL) | 58.77 ± 17.28 (18) | 65.42 ± 16.79 (16) | 0.270 | |
| VLDL-Cholesterol (mg/dL) | 40 ± 15 (19) | 40 ± 17 (13) | 0.910 | |
| LDL-Cholesterol (mg/dL) | 123 ± 48.36 (19) | 121.93 ± 50.49 (13) | 0.593 | |
| Triglycerides (mg/dL) | 201.1 (138–229.7) (18) | 207.3 (170.8–274) (15) | 0.580 | |
| Proteinuria | <0.001 | |||
| Proteinuria 0+ | 100% (20) | 30% (3) | ||
| Proteinuria 1+ | 30% (3) | |||
| Proteinuria 2+ | 30% (3) | |||
| Proteinuria 3+ | 10% (1) | |||
| Alanine Aminotransferase (U/L) | 15.1 (13.2–17.8) (20) | 19.3 (15.9–26.5) (16) | 0.010 | |
| Aspartate Aminotransferase (U/L) | 9.0 (7.8–12.0) (19) | 12.4 (11.0–19.5) (16) | 0.020 | |
| Lactate Dehydrogenase (U/L) | 185.5 (175–206) (18) | 241.5 (209.5–317) (16) | <0.001 | |
| Urea (mg/dL) | 14.2 (12.6–15.8) (20) | 24.4 (16.7–30.8) (16) | 0.001 | |
| Creatinine (mg/dL) | 0.61 ± 0.13 (20) | 0.72 ± 0.23 (16) | 0.008 | |
| Uric Acid (mg/dL) | 4.45 (3.85–4.80) (20) | 5.8 (5.7–7.2) (16) | <0.001 | |
| Sodium (mEq/L) | 138.06 ± 1.77 (16) | 137.48 ± 2.42 (12) | 0.492 | |
| Potassium (mEq/L) | 3.99 ± 0.27 (18) | 4.29 ± 0.34 (12) | 0.021 | |
| Indirect Bilirubin (mg/dL) | 0.25 ± 0.12 (19) | 0.21 ± 0.13 (11) | 0.437 | |
| Total Bilirubin (mg/dL) | 0.41 ± 0.16 (19) | 0.39 ± 0.18 (14) | 0.573 | |
| Iron (mg/dL) | 93.66 ± 37.37 (18) | 94.46 ± 41.04(15) | 0.594 | |
| Ferritin (ng/mL) | 29.1 (20.6–25.66) (17) | 39.3 (26.5–106.5) (15) | 0.105 | |
| Human Serum Albumin (g/dL) | 3.41 ± 0.27 (18) | 3.26 ± 0.4 (12) | 0.286 | |
| RI | 0.78 (0.75–0.80) (18) | 0.69 (0.64–0.74) (13) | 0.020 | |
| PI | 1.93 ± 0.54 (18) | 1.51 ± 0.37 (13) | 0.017 | |
| PSV (cm/s) | 31.4 (28.5–37.3) (19) | 30.6 (26.3–40.1) (13) | 0.570 | |
| P2 (cm/s) | 16.5 (14.6–24.3) (19) | 23.8 (20.1–24.5) (13) | 0.045 | |
| PR | 0.56 ± 0.13 (19) | 0.75 ± 0.14 (13) | 0.001 | |
| Vmean (cm/s) | 12.46 (10.6–17.03) (18) | 14.93 (12.73–17.82) (13) | 0.125 | |
| EDV (cm/s) | 6.81 (5.98–11.74) (19) | 9.88 (7.21–10.43) (12) | 0.164 | |
| Amin (ΔOD) | 1.086 ± 0.991 (18) | 0.968 ± 0.205 (16) | 0.048 | |
| Amax (ΔOD) | 0.015 (0.004–0.020) (18) | 0.013 (0.006–0.023) (16) | 0.959 | |
| Ho (g/dL NaCl) | 0.476 ± 0.022 (18) | 0.470 ± 0.029 (16) | 0.515 | |
| H50 (g/dL NaCl) | 0.442 (0.432–0.460) (18) | 0.431 (0.410–0.452) (16) | 0.187 | |
| H100 (g/dL NaCl) | 0.423 (0.398–0.427) (18) | 0.391 (0.381–0.414) (16) | 0.154 | |
| 1/H50 (g/dL NaCl)-1 | 2.264 (2.174–2.313) (18) | 2.317 (2.210–2.441) (16) | 0.187 | |
| dX (g/dL NaCl) | 0.016 (0.013–0.019) (18) | 0.020 (0.012–0.026) (16) | 0.376 | |
| dX/H50 | 0.036 (0.029–0.047) (18) | 0.042 (0.026–0.059) (16) | 0.506 | |
| dx/Amin | 0.016 (0.012–0.018) (18) | 0.017 (0.010–0.032) (16) | 0.347 | |
| Ammax (ΔOD) | 0.638 (0.569–0.714) (20) | 0.594 (0.503–0.668) (16) | 0.336 | |
| t1/2 (s) | 1.33 (0.77–2.00) (20) | 1.36 (0.99–2.50)(16) | 0.404 |
§Qualitative variables, expressed as percentage and compared with use of the chi-squared test.
*Non-normally distributed data, expressed as median (Q1-Q3) and compared with use of the Mann-Whitney test.
†Normally distributed data, expressed as mean ± SD and compared with use of Student t test.
Abbreviations: N, number of participants; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; MPV, mean platelet volume; HDL, high density lipoprotein; VLDL, very low density lipoprotein; LDL, low density lipoprotein; RI, resistance index; PI, pulsatility index; PSV, peak systolic velocity; P2, second peak of systolic velocity; PR, peak ratio; Vmean, mean velocity; EDV, end diastolic velocity; Amin, absorbance at 540 nm associated with residual lysis of the erythrocytes population; Amax, absorbance at 540 nm associated with lysis of the whole population of erythrocytes; H0, saline concentration where in vitro hemolysis begins; H50, saline concentration capable of promoting 50% hemolysis, H100, saline concentration where in vitro lysis ends; 1/H50, inverse the NaCl concentration capable of promoting 50% hemolysis; dX, variation in the concentration of NaCl responsible for total hemolysis; Ammax, absorbance at 540 nm associated with the mechanical lysis of the whole population of RBC; t1/2, time interval required for mechanical lysis of half of the erythrocyte population.
Fig 4Values of ρ coefficients for significant (p<0.05) Spearman correlations between some pairs of variables in pregnant women with preeclampsia.
Red and blue shading were used for positive and negative correlations, respectively. Abbreviations: MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; VLDL-C, very low density lipoprotein cholesterol; PSV, peak systolic velocity; P2, second peak of systolic velocity; PR, peak ratio; Amin, absorbance at 540 nm associated with residual lysis of the erythrocytes population; dX, variation in the concentration of NaCl responsible for total hemolysis; H50, saline concentration capable of promoting 50% hemolysis; Ammax, absorbance at 540 nm associated with the mechanical lysis of the whole population of RBC.